Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma

M. Agulnik, B. A. van Tine, S. Attia, A. Rademaker, M. Milhem, S. H. Okuno

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)viii592
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this